机构：[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/National Clinical Research Center for Anticancer Drug/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[3]Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China[4]Department of Breast Surgery, The Fourth Hospital, Hebei Medical University, Shijiazhuang, China河北医科大学第四医院外一科临床科室[5]Department of Breast Surgery, The First Affiliated Hospital, China Medical University, Shenyang, China[6]Department of Breast Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[7]Department of Breast Oncology, The Second Affiliated Hospital, Dalian Medical University, Dalian, China[8]Department of Breast Surgery, Guangdong General Hospital, Guangzhou, China广东省人民医院[9]Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China[10]Department of Breast Oncology, Fujian Cancer Hospital, Fuzhou, China[11]Department of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第二医院[12]Department of Breast Surgery, Renji Hospital, Shanghai Jiaotong University, Shanghai, China[13]Department of Breast Oncology, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[14]Department of Breast Oncology, Hunan Cancer Hospital, Changsha, China[15]Department of Medical Oncology, Anhui Provincial Hospital, Hefei, China[16]Department of Breast Surgery, Ruijin Hospital of Shanghai Jiaotong University, Shanghai, China[17]Department of Breast Oncology, Liaoning Cancer Hospital, Shenyang, China[18]Department of Breast Oncology, Cancer Hospital, Tianjin Medical University, Tianjin, China[19]Department of Breast Surgery, Affiliated Hospital of Medical College, Qingdao University, Qingdao, China[20]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[21]Department of Breast Oncology, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing, China[22]Department of Breast Oncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[23]Department of Breast Surgery, Shandong Cancer Hospital, Jinan, China[24]Department of Breast Surgery, Fudan University Shanghai Cancer Center, Harbin, China[25]Department of Breast Disease, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[26]Department of Medical Oncology, People's Liberation Army General Hospital, Beijing, China[27]Department of Breast Surgery, Cancer Hospital, Tianjin Medical University, Beijing, China[28]Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, China[29]Department of Breast Oncology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院
Breast cancer is the most common malignant tumor among women in the world. In 2005, there were approximately 272,000 new cases diagnosed and more than 70,000 deaths from breast cancer in China. Of the patients who are newly diagnosed with breast cancer each year, approximately 3% to 10% have distant metastases at the time of diagnosis. Of those who have early stage disease at diagnosis, from 30% to 40% will develop advanced breast cancer. The 5-year survival rate for patients with advanced breast cancer is only 20%, and the median overall survival (OS) is 2 to 3 years. Although advanced breast cancer is still difficult to cure, physicians can relieve clinical symptoms, improve quality of life, and further prolong survival through the development of new drugs and the optimization model of treatment. Patients with advanced breast cancer have their own preferences in the choice of treatment options. Moreover, there is no standard recommendation for the treatment of refractory breast cancer after multiline therapy. To offer a reference for clinicians, a Chinese expert group has analyzed, summarized, and discussed related research data on the diagnosis, treatment, and prognosis of inoperable, locally advanced breast cancer and recurrent or metastatic breast cancer and has developed the Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma (2018).
第一作者机构：[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/National Clinical Research Center for Anticancer Drug/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[*1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/National Clinical Research Center for Anticancer Drug/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
通讯作者：
通讯机构：[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/National Clinical Research Center for Anticancer Drug/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[*1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/National Clinical Research Center for Anticancer Drug/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
推荐引用方式(GB/T 7714)：
Binghe Xu,Xichun Hu,Jifeng Feng,et al.Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)[J].CANCER.2020,126:3867-3882.doi:10.1002/cncr.32832.
APA：
Binghe Xu,Xichun Hu,Jifeng Feng,Cuizhi Geng,Feng Jin...&Hong Zheng.(2020).Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018).CANCER,126,
MLA：
Binghe Xu,et al."Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)".CANCER 126.(2020):3867-3882
医学